Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

  title={Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial},
  author={M. Morrow},
  journal={Yearbook of Medicine},
  • M. Morrow
  • Published 2007
  • Medicine
  • Yearbook of Medicine
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes. Expand
Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools
The results showed that barriers are time constraints, lack of knowledge, low health literacy, and language barriers, and facilitators are information needs, desire for personalization, and autonomy when communicating risk in patient-provider encounters. Expand
Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches
Over the past three decades great efforts have been made in search of cancer chemoprevention strategies, but these strategies have yet to find clinical application on a large scale. Expand
Chemopreventive activity of tocopherols in mammary tumorigenesis
It is shown here how the representation of atoms and molecules in a graph shows the role that language plays in the development of knowledge. Expand
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Use of tamoxifen and raloxifene for prevention of primary breast cancers continues to be low, and in 2010, women reporting medication use for breast cancer chemoprevention were primarily using the more recently FDA approved drug ral oxifene. Expand
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene
The emerging evidence of the efficacy of raloxifene in postmenopausal women is reviewed, and emerging clinical evidence suggests bisphosphonates, currently used as drugs for the treatment of osteoporosis, may also reduce breast cancer risk. Expand
Breast Cancer Prevention: An Update of the STAR Trial
  • T. Bevers
  • Medicine
  • Current treatment options in oncology
  • 2010
This current analysis of the STAR trail provides updated results based on a median of 81 months of follow-up that raloxifene was as effective as tamoxifen at reducing breast cancer risk but with fewer side effects. Expand
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
  • S. Temin
  • Medicine
  • Gynecologic oncology
  • 2009
An expert panel reviewed the literature and developed updated consensus guidelines on pharmacologic interventions for breast cancer risk reduction, finding no evidence exists establishing whether a reduction in BC risk from either agent translates into reduced BC mortality. Expand
Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators
A rich oxidative chemistry for the benzothiophene SERMs is demonstrated, the amplitude of which can be powerfully modulated, in a predictable manner, by structural tuning of the 4′-substituent. Expand
[How to prevent early postmenopausal fracture risk? Proposition of a strategy].
HRT or raloxifene, which allows a more global approach of the menopause-induced consequences of estrogen deficiency than the sole prevention of osteoporosis, should be privileged within the first 10 years of treatment or so in those youngest women at increased risk for subsequent fracture. Expand


Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Acceptance of tamoxifen chemoprevention by physicians and women at risk
The purpose of the current study was to identify factors associated with being offered, and accepting, tamoxifen chemoprevention. Expand
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe. Expand